Normal intrathecal leukocyte cell number and composition do not decrease the incidence of post–lumbar puncture headache

Olaf Stüve, Fabio Cataldi, Vivek Pradhan, Kenneth J. Gorelick

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The pathogenesis of post–lumbar puncture headache (PLPH) has remained unclear. A beneficial role of CSF cells in the repair of a post-traumatic dural CSF leak has been suggested. The primary purpose of this study was to investigate the effects of 8 weeks of induction therapy with high-dose PF-00547659 on the cellular elements of CNS immune surveillance in patients with active Crohn's Disease and a history of immunosuppressive therapy (Clinicaltrials.gov NCT01387594). PF-00547659 is a human monoclonal antibody that binds to mucosal addressin–cell adhesion molecule 1 (MAdCAM-1) on endothelial cells and blocks its interaction with beta7-integrin expressing lymphocytes. The study was executed in three parts or cohorts under two protocols. The incidence of a PLPH was 35% after the initial lumbar puncture, and 26% following the second lumbar puncture. After initiation of PF-00547659 anti-MAdCAM-1 therapy, there was a small and non-significant increase in the numbers of overall CSF leukocytes, and in lymphocyte subsets (CD3 +, CD4 +, and CD8 + T cells). The lymphocyte composition was unaltered by PF-00547659 anti-MAdCAM-1 therapy. Our observations suggest that normal numbers and composition of intrathecal leukocytes do not decrease the incidence of PLPH.

Original languageEnglish (US)
Pages (from-to)69-71
Number of pages3
JournalJournal of Neuroimmunology
Volume310
DOIs
StatePublished - Sep 15 2017

Fingerprint

Leukocyte Count
Punctures
Headache
Cell Count
Spinal Puncture
Incidence
Leukocytes
Lymphocytes
Lymphocyte Subsets
Therapeutics
Immunosuppressive Agents
Crohn Disease
Endothelial Cells
Monoclonal Antibodies
T-Lymphocytes
PF-00547659

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Cite this

Normal intrathecal leukocyte cell number and composition do not decrease the incidence of post–lumbar puncture headache. / Stüve, Olaf; Cataldi, Fabio; Pradhan, Vivek; Gorelick, Kenneth J.

In: Journal of Neuroimmunology, Vol. 310, 15.09.2017, p. 69-71.

Research output: Contribution to journalArticle

@article{24e41490efee4dc2a23a8ad8e6469f65,
title = "Normal intrathecal leukocyte cell number and composition do not decrease the incidence of post–lumbar puncture headache",
abstract = "The pathogenesis of post–lumbar puncture headache (PLPH) has remained unclear. A beneficial role of CSF cells in the repair of a post-traumatic dural CSF leak has been suggested. The primary purpose of this study was to investigate the effects of 8 weeks of induction therapy with high-dose PF-00547659 on the cellular elements of CNS immune surveillance in patients with active Crohn's Disease and a history of immunosuppressive therapy (Clinicaltrials.gov NCT01387594). PF-00547659 is a human monoclonal antibody that binds to mucosal addressin–cell adhesion molecule 1 (MAdCAM-1) on endothelial cells and blocks its interaction with beta7-integrin expressing lymphocytes. The study was executed in three parts or cohorts under two protocols. The incidence of a PLPH was 35{\%} after the initial lumbar puncture, and 26{\%} following the second lumbar puncture. After initiation of PF-00547659 anti-MAdCAM-1 therapy, there was a small and non-significant increase in the numbers of overall CSF leukocytes, and in lymphocyte subsets (CD3 +, CD4 +, and CD8 + T cells). The lymphocyte composition was unaltered by PF-00547659 anti-MAdCAM-1 therapy. Our observations suggest that normal numbers and composition of intrathecal leukocytes do not decrease the incidence of PLPH.",
author = "Olaf St{\"u}ve and Fabio Cataldi and Vivek Pradhan and Gorelick, {Kenneth J.}",
year = "2017",
month = "9",
day = "15",
doi = "10.1016/j.jneuroim.2017.06.011",
language = "English (US)",
volume = "310",
pages = "69--71",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",

}

TY - JOUR

T1 - Normal intrathecal leukocyte cell number and composition do not decrease the incidence of post–lumbar puncture headache

AU - Stüve, Olaf

AU - Cataldi, Fabio

AU - Pradhan, Vivek

AU - Gorelick, Kenneth J.

PY - 2017/9/15

Y1 - 2017/9/15

N2 - The pathogenesis of post–lumbar puncture headache (PLPH) has remained unclear. A beneficial role of CSF cells in the repair of a post-traumatic dural CSF leak has been suggested. The primary purpose of this study was to investigate the effects of 8 weeks of induction therapy with high-dose PF-00547659 on the cellular elements of CNS immune surveillance in patients with active Crohn's Disease and a history of immunosuppressive therapy (Clinicaltrials.gov NCT01387594). PF-00547659 is a human monoclonal antibody that binds to mucosal addressin–cell adhesion molecule 1 (MAdCAM-1) on endothelial cells and blocks its interaction with beta7-integrin expressing lymphocytes. The study was executed in three parts or cohorts under two protocols. The incidence of a PLPH was 35% after the initial lumbar puncture, and 26% following the second lumbar puncture. After initiation of PF-00547659 anti-MAdCAM-1 therapy, there was a small and non-significant increase in the numbers of overall CSF leukocytes, and in lymphocyte subsets (CD3 +, CD4 +, and CD8 + T cells). The lymphocyte composition was unaltered by PF-00547659 anti-MAdCAM-1 therapy. Our observations suggest that normal numbers and composition of intrathecal leukocytes do not decrease the incidence of PLPH.

AB - The pathogenesis of post–lumbar puncture headache (PLPH) has remained unclear. A beneficial role of CSF cells in the repair of a post-traumatic dural CSF leak has been suggested. The primary purpose of this study was to investigate the effects of 8 weeks of induction therapy with high-dose PF-00547659 on the cellular elements of CNS immune surveillance in patients with active Crohn's Disease and a history of immunosuppressive therapy (Clinicaltrials.gov NCT01387594). PF-00547659 is a human monoclonal antibody that binds to mucosal addressin–cell adhesion molecule 1 (MAdCAM-1) on endothelial cells and blocks its interaction with beta7-integrin expressing lymphocytes. The study was executed in three parts or cohorts under two protocols. The incidence of a PLPH was 35% after the initial lumbar puncture, and 26% following the second lumbar puncture. After initiation of PF-00547659 anti-MAdCAM-1 therapy, there was a small and non-significant increase in the numbers of overall CSF leukocytes, and in lymphocyte subsets (CD3 +, CD4 +, and CD8 + T cells). The lymphocyte composition was unaltered by PF-00547659 anti-MAdCAM-1 therapy. Our observations suggest that normal numbers and composition of intrathecal leukocytes do not decrease the incidence of PLPH.

UR - http://www.scopus.com/inward/record.url?scp=85021742392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021742392&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2017.06.011

DO - 10.1016/j.jneuroim.2017.06.011

M3 - Article

C2 - 28778448

AN - SCOPUS:85021742392

VL - 310

SP - 69

EP - 71

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

ER -